Anaplastic Astrocytoma, Glioblastoma Multiforme
Conditions
Keywords
Recurrence
Brief summary
This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation status. A second stratification factor is based on the patient's Karnofsky Performance Score (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices for the control arm in regions, the trial will be stratified by geographical region during the randomization process. Funding Source - FDA OOPD
Interventions
BIOLOGICALToca 511
Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
DRUGToca FC
Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
DRUGLomustine
DRUGTemozolomide
BIOLOGICALBevacizumab
Sponsors
Tocagen Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subject has given written informed consent 2. Subject is between 18 years old and 75 years old, inclusive 3. Subjects must have histologically proven GBM or AA and: 1. Must have received first-line multimodal therapy with surgery followed by temozolomide (unless MGMT promoter unmethylated) and radiation (subjects with GBM must have received temozolomide and radiation concurrently) 2. Must be in first or second recurrence (including this recurrence) 3. Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI. If first recurrence of GBM is documented by MRI, an interval of at least 12 weeks after the end of prior radiation therapy is required unless there is either: i) histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field 4. Subjects must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria 5. Subjects must be at least 4 weeks post last dose of temozolomide 6. Prior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is allowed but the subject must have either histopathologic confirmation of recurrent tumor, or new enhancement on MRI outside of the radiotherapy treatment field 7. Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for ≥ 80% resection of enhancing region 8. IDH mutation status of the primary tumor must be available or tumor samples must be available for pre randomization testing 9. Laboratory values adequate for patient to undergo surgery, including: * Platelet count ≥ 60,000/mm3 * Hgb ≥ 10 g/dL * Absolute neutrophil count (ANC) ≥ 1,500/mm3 * Absolute lymphocyte count (ALC) ≥ 500/mm3 * Adequate liver function, including: * Total bilirubin ≤ 1.5 x ULN (unless has Gilbert's syndrome) * ALT ≤ 2.5 x ULN f. Estimated glomerular filtration rate of at least 50 mL/min by the Cockcroft Gault formula 10. Women of childbearing potential (≥12 months of non-therapy-induced amenorrhea or surgically sterile) must have had a negative serum pregnancy test within the past 21 days and must use a birth control method in addition to barrier methods (condoms). 11. Subject or subject's partner is willing to use condoms for 12 months after receiving Toca 511 or until there is no evidence of the virus in his/her blood, whichever is longer. 12. The subject has a KPS ≥ 70 13. The subject is willing and able to abide by the protocol
Exclusion criteria
1. History of more than 2 prior recurrences (including this recurrence) of GBM or AA 2. History of other malignancy, unless the patient has been disease free for at least 5 years. Adequately treated basal cell carcinoma or squamous cell skin cancer is acceptable regardless of time, as well as localized prostate carcinoma or cervical carcinoma in situ after curative treatment 3. Histologically confirmed oligodendroglioma or mixed glioma 4. Known 1p/19q co deletion 5. A contrast enhancing brain tumor that is any of the following: * Multi focal (defined as 2 separate areas of contrast enhancement measuring at least 1 cm in 2 planes that are not contiguous on either fluid attenuated inversion recovery (FLAIR) or T2 sequences); * Associated with either diffuse subependymal or leptomeningeal dissemination; or * \> 5 cm in any dimension 6. The subject has or had any active infection requiring systemic antibiotic, antifungal or antiviral therapy within the past 4 weeks 7. The subject has any bleeding diathesis, or must take anticoagulants, or antiplatelet agents, including nonsteroidal anti inflammatory drugs (NSAIDs), at the time of the scheduled resection that cannot be stopped for surgery 8. The subject is human immunodeficiency virus (HIV) positive 9. The subject has a history of allergy or intolerance to flucytosine 10. The subject has a gastrointestinal disease that would prevent him or her from being able to swallow or absorb flucytosine 11. The subject received cytotoxic chemotherapy within the past 4 weeks (6 weeks for nitrosoureas) of the planned surgery date 12. The subject received any investigational treatment within the past 30 days or prior immunotherapy or antibody therapy within the past 45 days. 13. The subject is pregnant or breast feeding 14. The subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery or has received the Gliadel® wafer \< 30 days from W1D1 (surgery) 15. The subject has received bevacizumab for their disease unless in the context of primary therapy for newly diagnosed glioma 16. For subjects planned to potentially receive bevacizumab, they have no evidence of uncontrolled hypertension (defined as a blood pressure of ≥ 150 mm Hg systolic and/or ≥ 100 mm Hg diastolic on medication) or active GI perforation 17. The subject has received systemic dexamethasone continuously at a dose \> 8 mg/day for 8 weeks prior to the date of the screening assessment 18. Severe pulmonary, cardiac or other systemic disease, specifically: * New York Heart Association \> Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication * Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades des pointes), clinically significant pulmonary disease (such as ≥ Grade 2 dyspnea, according to CTCAE 4.03) * Subjects who have any other disease, either metabolic or psychological, which as per Investigator assessment may affect the subject's compliance or place the subject at higher risk of potential treatment complications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma | 30 December 2019 | Time from randomization date to death due to any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Durable Response Rate (CR or PR ≥ 24 weeks) | 30 December 2019 | The proportion of patients whose best response is either CR or PR lasting at least 24 weeks, according to modified RANO criteria |
| Durable Clinical Benefit Rate (CR or PR ≥ 24 weeks or SD ≥ 18 months) | 30 December 2019 | The proportion of subjects whose best overall response is either CR or PR lasting at least 24 weeks, or stable disease (SD) lasting at least 18 months, according to modified RANO criteria |
| Duration of Durable Response | 30 December 2019 | Time from documentation of durable response to disease progression or death due to disease progression |
| Overall Survival at 12 months | 30 December 2019 | Time from randomization date to death due to any cause |
Countries
Canada, Israel, South Korea, United States
Outcome results
None listed